^
BIOMARKER:

STK11 mutation

i
Other names: Serine/Threonine-Protein Kinase 11, Liver Kinase B1, Serine/Threonine-Protein Kinase LKB1, Polarization-Related Protein LKB1, STK11, Serine/Threonine Kinase 11, Serine/Threonine-Protein Kinase STK11, Renal Carcinoma Antigen NY-REN-19
Entrez ID:
Related biomarkers:
STK11 mutation
NSCLC
nivolumab
Resistant: B - Late Trials
STK11 mutation
NSCLC
DRP-104
Sensitive: B - Late Trials
STK11 mutation
NSCLC
durvalumab
Resistant: B - Late Trials
STK11 mutation
Lung Non-Squamous Non-Small Cell Cancer
docetaxel
Resistant: C3 – Early Trials
STK11 mutation
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Resistant: C3 – Early Trials
STK11 mutation
Lung Non-Squamous Non-Small Cell Cancer
rivoceranib + camrelizumab
Sensitive: C3 – Early Trials
STK11 mutation
NSCLC
pembrolizumab
Resistant: C3 – Early Trials
STK11 mutation
NSCLC
Immunotherapy
Resistant: C3 – Early Trials
STK11 mutation
NSCLC
PD-L1 inhibitor
Sensitive: C3 – Early Trials
STK11 mutation
NSCLC
cetuximab + avelumab
Resistant: C3 – Early Trials
STK11 mutation
LUAD
Immunotherapy
Resistant: C3 – Early Trials
STK11 mutation
NSCLC
atezolizumab
Resistant: C3 – Early Trials
STK11 mutation
Lung Non-Squamous Non-Small Cell Cancer
durvalumab + CP-675206
Resistant: C3 – Early Trials
STK11 mutation
Lung Non-Squamous Non-Small Cell Cancer
durvalumab
Resistant: C3 – Early Trials
STK11 mutation
Cervical Cancer
anlotinib + sintilimab
Resistant: C3 – Early Trials
STK11 mutation
Pituitary Gland Carcinoma
temozolomide + capecitabine
Resistant: C4 – Case Studies
STK11 mutation
Pituitary Gland Carcinoma
everolimus
Sensitive: C4 – Case Studies
STK11 mutation
Pancreatic Cancer
everolimus
Sensitive: C4 – Case Studies
STK11 mutation
Lung Non-Small Cell Squamous Cancer
pembrolizumab
Resistant: C4 – Case Studies
STK11 mutation
LUAD
abemaciclib
Sensitive: C4 – Case Studies
STK11 mutation
NSCLC
APG-115
Sensitive: D – Preclinical
STK11 mutation
Lung Cancer
dasatinib + selumetinib + RTB101
Sensitive: D – Preclinical
STK11 mutation
Lung Cancer
dasatinib
Resistant: D – Preclinical
STK11 mutation
NSCLC
sirolimus
Sensitive: D – Preclinical
STK11 mutation
NSCLC
CI-1040
Sensitive: D – Preclinical
STK11 mutation
NSCLC
JQ-1
Resistant: D – Preclinical